Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

GPR55: A therapeutic target for Parkinson's disease?
Marta Celorrio, Estefanía Rojo-Bustamante, Diana Fernández‐Suárez, et al.
Neuropharmacology (2017) Vol. 125, pp. 319-332
Closed Access | Times Cited: 91

Showing 1-25 of 91 citing articles:

Diversity of molecular targets and signaling pathways for CBD
Douglas Lamounier de Almeida, Lakshmi A. Devi
Pharmacology Research & Perspectives (2020) Vol. 8, Iss. 6
Open Access | Times Cited: 192
G protein-coupled receptors in neurodegenerative diseases and psychiatric disorders
Thian‐Sze Wong, Guangzhi Li, Shiliang Li, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 60
Cannabidiol as a Promising Strategy to Treat and Prevent Movement Disorders?
Fernanda Fiel Peres, Alvaro C. Lima, Jaime E. C. Hallak, et al.
Frontiers in Pharmacology (2018) Vol. 9
Open Access | Times Cited: 156
Effects of cannabidiol (CBD) in neuropsychiatric disorders: A review of pre-clinical and clinical findings
Sonja Elsaid, Stefan Kloiber, Bernard Le Foll
Progress in molecular biology and translational science (2019), pp. 25-75
Closed Access | Times Cited: 119
From Cannabis sativa to Cannabidiol: Promising Therapeutic Candidate for the Treatment of Neurodegenerative Diseases
Tommaso Cassano, Rosanna Villani, Lorenzo Pace, et al.
Frontiers in Pharmacology (2020) Vol. 11
Open Access | Times Cited: 118
Cannabidiol as a Therapeutic Target: Evidence of its Neuroprotective and Neuromodulatory Function in Parkinson’s Disease
Felipe Patricio, Alan Axel Morales-Andrade, Aleidy Patricio-Martínez, et al.
Frontiers in Pharmacology (2020) Vol. 11
Open Access | Times Cited: 96
Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system
Marta Aymerich, Ester Aso, Miguel Angel Abellanas, et al.
Biochemical Pharmacology (2018) Vol. 157, pp. 67-84
Open Access | Times Cited: 95
Lysophosphatidylinositols, from Cell Membrane Constituents to GPR55 Ligands
Mireille Alhouayek, Julien Masquelier, Giulio G. Muccioli
Trends in Pharmacological Sciences (2018) Vol. 39, Iss. 6, pp. 586-604
Closed Access | Times Cited: 89
Some Prospective Alternatives for Treating Pain: The Endocannabinoid System and Its Putative Receptors GPR18 and GPR55
Raquel Guerrero‐Alba, Paulino Barragán‐Iglesias, Abimael González‐Hernández, et al.
Frontiers in Pharmacology (2019) Vol. 9
Open Access | Times Cited: 87
Molecular Targets of Cannabidiol in Experimental Models of Neurological Disease
Serena Silvestro, Giovanni Schepici, Placido Bramanti, et al.
Molecules (2020) Vol. 25, Iss. 21, pp. 5186-5186
Open Access | Times Cited: 71
An overview on synthetic and biological activities of cannabidiol (CBD) and its derivatives
Xiuli Wang, Huanbang Zhang, Yan Liu, et al.
Bioorganic Chemistry (2023) Vol. 140, pp. 106810-106810
Closed Access | Times Cited: 26
Cannabidiol-Loaded Nanocarriers and Their Therapeutic Applications
Elham Assadpour, Atefe Rezaei, Sabya Sachi Das, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 4, pp. 487-487
Open Access | Times Cited: 23
Therapeutic applicability of cannabidiol and other phytocannabinoids in epilepsy, multiple sclerosis and Parkinson's disease and in comorbidity with psychiatric disorders
Maria de Fátima dos Santos Sampaio, Yara Bezerra de Paiva, Tuane Bazanella Sampaio, et al.
Basic & Clinical Pharmacology & Toxicology (2024) Vol. 134, Iss. 5, pp. 574-601
Open Access | Times Cited: 11
Structural basis for lipid-mediated activation of G protein-coupled receptor GPR55
Tobias Claff, R. Ebenhoch, Jörg T. Kley, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 1
Palmitoylethanolamide (PEA) as a Potential Therapeutic Agent in Alzheimer’s Disease
Sarah Beggiato, Maria Cristina Tomasini, Luca Ferraro
Frontiers in Pharmacology (2019) Vol. 10
Open Access | Times Cited: 72
Anti-neuroinflammatory effects of GPR55 antagonists in LPS-activated primary microglial cells
Soraya Wilke Saliba, Hannah Jauch, Brahim Gargouri, et al.
Journal of Neuroinflammation (2018) Vol. 15, Iss. 1
Open Access | Times Cited: 66
Haloperidol‐induced catalepsy as an animal model for parkinsonism: A systematic review of experimental studies
Isabelle Waku, Mylena S. Magalhães, Camila de Oliveira Alves, et al.
European Journal of Neuroscience (2021) Vol. 53, Iss. 11, pp. 3743-3767
Closed Access | Times Cited: 47
Neuroprotective potential of cannabidiol: Molecular mechanisms and clinical implications
Srushti Tambe, Suraj N. Mali, Purnima Amin, et al.
Journal of Integrative Medicine (2023) Vol. 21, Iss. 3, pp. 236-244
Closed Access | Times Cited: 17
Different receptor mechanisms underlying phytocannabinoid‐ versus synthetic cannabinoid‐induced tetrad effects: Opposite roles of CB 1 /CB 2 versus GPR55 receptors
Xiao‐Fei Wang, Ewa Galaj, Guo‐Hua Bi, et al.
British Journal of Pharmacology (2019) Vol. 177, Iss. 8, pp. 1865-1880
Open Access | Times Cited: 43
Recent Advances in the Potential of Cannabinoids for Neuroprotection in Alzheimer’s, Parkinson’s, and Huntington’s Diseases
Catalina Pérez-Olives, Rafael Rivas‐Santisteban, Jaume Lillo, et al.
Advances in experimental medicine and biology (2020), pp. 81-92
Closed Access | Times Cited: 43
Activation of GPR55 attenuates cognitive impairment, oxidative stress, neuroinflammation, and synaptic dysfunction in a streptozotocin-induced Alzheimer's mouse model
XiaoTong Xiang, Xin Wang, Yumei Wu, et al.
Pharmacology Biochemistry and Behavior (2022) Vol. 214, pp. 173340-173340
Closed Access | Times Cited: 26
Roles of the Cannabinoid System in the Basal Ganglia in Parkinson’s Disease
Mengya Wang, Huayuan Liu, Zegang Ma
Frontiers in Cellular Neuroscience (2022) Vol. 16
Open Access | Times Cited: 23
GPR55 is expressed in glutamate neurons and functionally modulates drug taking and seeking in rats and mice
Yi He, Hui Shen, Guo‐Hua Bi, et al.
Translational Psychiatry (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 5
Advance in Vascular Anomalies of Head and Neck Region: From Bench to Bedside
Deming Wang
Frontiers research topics (2025)
Closed Access
Discovering promising drug candidates for Parkinson’s disease: integrating miRNA and DEG analysis with molecular dynamics and MMPBSA
Bisma Ishtiaq, Rehan Zafar Paracha, Maryum Nisar, et al.
Journal of Computer-Aided Molecular Design (2025) Vol. 39, Iss. 1
Closed Access
Page 1 - Next Page

Scroll to top